| Followers | 73 |
| Posts | 3426 |
| Boards Moderated | 1 |
| Alias Born | 04/28/2004 |
Thursday, June 24, 2004 3:10:22 PM
It appears that the ARQL phase I is a simple dose ascending trial in cohorts of 3 patients. The claim to date is that they have not yet run into the MTD; once they do, it is my impression that they will focus on one cancer and run another small trial to look for an objective response or two.
The concept of checkpoint therapy is interesting. Nonetheless, I can see a very real possibility of arq501 falling flat on its face... sometimes drugs that have no toxicity also have no efficacy
My exposure is limited, and it helps to know that arql is perceived to be one of the better chem outfits. It should help their liquidity situation while they pursue their oncology program.
The concept of checkpoint therapy is interesting. Nonetheless, I can see a very real possibility of arq501 falling flat on its face... sometimes drugs that have no toxicity also have no efficacy
My exposure is limited, and it helps to know that arql is perceived to be one of the better chem outfits. It should help their liquidity situation while they pursue their oncology program.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
